login
Password reminder
Cardiovascular News
Contact the editor Visit Cardiovascular News Twitter feed Visit Cardiovascular News Facebook page
 

First study to evaluate alternative to warfarin for mechanical heart valve patients launched


Thursday, 21 Jun 2012 11:55



The American Heart Journal has published the design of the RE-ALIGN study, the first study to evaluate dabigatran etexilate (Pradaxa, Boehringer Ingelheim) as alternative to warfarin for use in patients with mechanical heart valves requiring anticoagulation therapy.


RE-ALIGN (Randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement) addresses current limitations experienced with warfarin and is designed to identify safe and effective dosing regimen of dabigatran for the prevention of valve thrombosis, stroke and systemic embolism in this patient population, prior to further investigation in a larger phase III study.The current approval of dabigatran does not cover the use in patients with mechanical heart valves.

Vitamin K antagonists, such as warfarin, are the current long-term standard for anticoagulation of patients with a cardiac valve replacement. However, there is only limited information available on the long-term risk of thrombotic and haemorrhagic complications associated with this therapy in patients with modern mechanical bileaflet valves. Additionally, in spite of frequent INR monitoring, patients treated with warfarin spend less that 65% of the time within the targeted therapeutic range (TTR), with TTR in the first three months following valve replacement surgery reported to be as low as 48.5%.


“It is vital that patients with mechanical heart valves are provided with anticoagulant therapies that are safe and effective over the long-term. The current treatment with vitamin K antagonists is associated with significant limitations, creating a need for novel options which have fewer interactions and do not require regular monitoring. We are proud to be the first company looking for an alternative option for these patients by investigating Pradaxa in the RE-ALIGN trial,” said Klaus Dugi, corporate senior vice president Medicine, Boehringer Ingelheim.


The RE-ALIGN study, a prospective, randomised, phase II study, evaluates dabigatran in patients with mechanical bileaflet heart valve during a follow-up period of 12 weeks.Based on the results, a sufficiently powered phase III study is planned to investigate efficacy outcomes for dabigatran in this patient population.


“Pradaxa has already been proven to be a safe and efficacious anticoagulant treatment for stroke prevention in patients with atrial fibrillation,” said Frans Van de Werf, Department of Cardiovascular Medicine, University Hospitals Leuven, Belgium. “However, the presence of a mechanical heart valve is a distinct clinical situation requiring different dosing. The aim of the RE-ALIGN study is to identify dosing regimens of Pradaxa that are expected to be safe and effective for the prevention of thromboembolic complications in patients with mechanical heart valves.”


The different dosing regimens that are under investigation for dabigatran in RE-ALIGN are 150mg bid, 220mg bid, and 300mg bid, with the starting dose determined by the individual patient’s creatinine clearance. The study includes patients with recent surgery for implantation of mechanical bileaflet heart valve who have not yet started oral anticoagulation, and patients who had surgery at least three months before randomisation and are currently taking an oral vitamin K antagonist. Patients are randomised to receive either dabigatran or warfarin. After the 12 week study period, patients are given the opportunity to opt-in to continue treatment with dabigatran within the RE-ALIGN extension trial, allowing investigators to collect long-term safety data.


To date, no investigation has been undertaken to determine the efficacy and safety of any novel oral anticoagulant including dabigatran in patients with mechanical heart valves. Until such data are available, the use of dabigatran for the prevention of thromboembolic complications in patients with mechanical heart valves is not recommended nor approved for clinical practice and is restricted to the setting of a randomised clinical trial only.




Add New Comment

Related Items


Most popular


European Union agrees new rules for approving medical devices and in vitro diagnostic medical devices
Tuesday, 31 May 2016
The Netherlands presidency of the European Council and representatives of the European Parliament have reached a political agreement on two draft regulations for medical devices. The new regulations ... European Union agrees new rules for approving medical devices and in vitro diagnostic medical devices

Karl-Heinz Kuck steps down from the ESC and EHRA after fraud conviction
Wednesday, 08 Jun 2016
Karl-Heinz Kuck has withdrawn his candidacy for president-elect of the European Society of Cardiology (ESC) and also resigned from board of the European Heart Rhythm Association (EHRA). This follows ... Karl-Heinz Kuck steps down from the ESC and EHRA after fraud conviction

Biotronik’s scaffold is now approved for use in Europe
Wednesday, 15 Jun 2016
Biotronik’s bioresorbable magnesium scaffold—Magmaris—is now CE mark approved, meaning it is now one of three bioresorbable scaffolds available on the European market (alongside Abbott Vascular’s A... Biotronik’s scaffold is now approved for use in Europe

Features


TAVI durability: A rose by any other name is still a rose
Wednesday, 20 Jul 2016
The data that Dvir presented at EuroPCR, as reported by Cardiovascular News, indicate that there is a significant increase in valve degeneration between five and seven years after a transcatheter ... TAVI durability: A rose by any other name is still a rose

Exploring the borders of TAVI
Monday, 11 Jul 2016
The NOTION 2 trial, which recently enrolled a 64-year-old female with Society of Thoracic Surgeon (STS) score 1.2% as its first patient, is comparing the use of TAVI with the use of surgical aortic ... Exploring the borders of TAVI

Profiles


James Blankenship
Wednesday, 08 Jun 2016
James Blankenship is the 2015–2016 president of SCAI and has been involved with designing and ... James Blankenship

Alexandra Lansky
Monday, 07 Mar 2016
Alexandra Lansky (Director, Heart and Vascular Clinical Research Program, Yale University School of ... Alexandra Lansky

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions